MN-ECOLAB-INC
18.9.2023 14:36:33 CEST | Business Wire | Press release
Ecolab, a global sustainability leader offering water solutions and services, today announced findings from the inaugural Ecolab Watermark™ Study. The global consumer research examined the state of water stewardship through water’s importance, usage, connection to climate and responsibility among key consumer populations around the world.
By 2030, the planet is set to face a 56% water deficit, according to the World Resources Institute, and 1.6 billion people will lack safely managed drinking water, according to the United Nations. It’s amid this pressing water crisis that Ecolab developed the Ecolab Watermark Study to identify trends, help educate and generate action across industry stakeholders, specifically those in Asia/Pacific, China, Europe, India/Middle East/Africa (IMEA), Latin America and the United States (U.S.).
Among its global findings, the Ecolab Watermark Study uncovered several critical water-related trends:
- Access to clean and safe water is a paramount concern for consumers in every region. Latin America (92%), China (85%) and the U.S. (81%) have the highest percentage of consumers who are more concerned about access to clean and safe water than other climate-related issues, such as pollution or climate change.
- Consumers hold governments and businesses most responsible for water conservation. However, consumers do not believe these leaders care enough about their impact on water or climate change. This was most pronounced in the U.S., Europe, Latin America and Asia/Pacific, where between 42% and 46% of people believed their leaders cared.
- Consumers believe that industry has no clear plan to address water scarcity, despite the perceived responsibility and importance. This concern is most evident in China (82%), Latin America (78%), and IMEA (78%), but also noticeably visible in Europe (66%), the U.S. (65%) and Asia/Pacific (60%).
“The water crisis impacts communities regardless of location and is often overlooked in the global response to climate change. As we continue our work to transform the way the world thinks about water, the results from the Ecolab Watermark Study should galvanize leaders to assume a larger role in protecting this precious and finite resource,” said Christophe Beck, chairman and chief executive officer, Ecolab. “Time is running out to address this challenge, and consumers across the world are saying that businesses must act now. The good news for industry is that meeting this responsibility can deliver positive sustainability and business outcomes.”
In response to the perceived lack of accountability, consumers are themselves adopting environmentally friendly buying behaviors. According to the study, consumers are willing to stop purchasing products that require a significant amount of water to produce, as well as pay more for goods that are made using sustainable business practices, particularly in IMEA (88%), China (85%) and Latin America (81%).
Despite the known challenges, consumers remain optimistic that the water crisis can be mitigated with proper and immediate action. On average, three out of four consumers across the globe believe that water scarcity can be effectively addressed, according to the study, with the optimism most evident in Latin America (84%), IMEA (83%) and China (78%).
“If industry is not at the table to advocate and develop climate and water solutions that protect our communities, we will continue to fuel consumer sentiment that we’re not doing enough,” said Emilio Tenuta, senior vice president and chief sustainability officer, Ecolab. “By focusing solely on water and consumer perceptions of the ongoing crisis, the Ecolab Watermark Study provides unique insights on where and how stakeholders—whether its government, businesses, NGOs or even individuals—can work together to successfully address critical global challenges.”
In addition to offering global and regional findings, the Ecolab Watermark Study includes data for 15 individual countries. The U.S.-specific data showed that 81% of consumers are concerned about access to clean and safe water, and they consider businesses and governments to have the highest level of responsibility when it comes to funding for water conservation. Plus, 65% of U.S. consumers agree that businesses and manufacturers lack clear guidance and plans to combat water scarcity. Lastly, even though less than half of U.S. consumers believe that business and government leaders care about climate change or water conservation, 70% remain optimistic that water scarcity can be effectively addressed.
The Ecolab Watermark Study was conducted in partnership with Morning Consult in 2023 among a sample of general population adults. Ecolab will update and release new editions of its Ecolab Watermark Study annually. For detailed results, including an interactive dashboard, visit watermark.ecolab.com.
About Ecolab
A trusted partner for millions of customers, Ecolab (NYSE:ECL) is a global sustainability leader offering water, hygiene and infection prevention solutions and services that protect people and the resources vital to life. Building on a century of innovation, Ecolab has annual sales of $14 billion, employs more than 47,000 associates and operates in more than 170 countries around the world. The company delivers comprehensive science-based solutions, data-driven insights and world-class service to advance food safety, maintain clean and safe environments, and optimize water and energy use. Ecolab’s innovative solutions improve operational efficiencies and sustainability for customers in the food, healthcare, life sciences, hospitality and industrial markets. www.ecolab.com
Follow us on LinkedIn @Ecolab, Twitter @Ecolab, Instagram @Ecolab_Inc and Facebook @Ecolab.
About the Ecolab Watermark™ Study
Launched in 2023, the Ecolab Watermark Study is annual research conducted by Ecolab. The global study reports on the state of water stewardship by measuring water’s importance, usage, connection to climate and responsibility among key consumer populations. This research was conducted between February 15 – March 3, 2023, among a sample of general population adults. The interviews were conducted online. Results from the full study have a margin of error of plus or minus 2–3 percentage points. Some geographies may be weighted with fewer variables depending on local census data availability.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230918273418/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
